iCas9-T2A-antiCD19scFv-CD28-CD3z

Item Information
Catalog #Size/ConcentrationPrice
Specification
ProductOrderI
Shipping InformationThis product will ship in a box containing dry ice at a temperature of -80°C. Learn More
Catalog#: PM-CAR1006
Inquire
Contact us to order
1-866-339-0871
510-740-3625
info@promab.com
Images
Illustration of CAR construct
Figure 1: CAR-T cells expressing the above construct are available from Promab targeting CD19 with inducible
Figure 1: CAR-T cells expressing the above construct are available from Promab targeting CD19 with inducible
Positive control measured with flow cytometry
Figure 2: Flow cytometry with Fab Ab showing expression of scFv icasp9-CD19 CAR T-cells.
Figure 2: Flow cytometry with Fab Ab showing expression of scFv icasp9-CD19 CAR T-cells.
Negative control measured with flow cytometry
Figure 3: T cells that have not been transfected.
Figure 3: T cells that have not been transfected.
Product Overview
Description

The inducible caspase-9-CD19 CAR construct consists of FKBP12 gene with mutation F36 to V coding two 12 kDa FK506 binding proteins fused to truncated Caspase9 (135-416; lacking pro-domain), followed by T2A peptide and then CD19scFv-CD28-CD3zeta. Administration of chemical inductor of dimerization (CID) CID (AP1903 or AP20187) results in dimerization of caspase 9 leading to an activated form of the molecule, which then initiates an apoptotic signaling leading to apoptosis of the transduced cell. Introduction of inducible caspase-9 is used for increasing safety of CAR-T cells by decreasing cytotoxicity of CAR-T cells in the presence of dimerization agent.

Please view FAQs here